Mode
Text Size
Log in / Sign up
N/A N=145 Treatment

Bipolar Ventricular Tachycardia (VT) Study

Ventricular Tachycardia

Enrolled (actual)
145
Serious AEs
46.8%
Results posted
Nov 2022
Primary outcome: Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bipolar Ablation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Srinivas Dukkipati
Primary completion
Apr 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)
16; 29
SECONDARY
Number of Procedural Complications
31; 19
SECONDARY
Number of Participants With Post-ablation Inducibility of VT
6; 5
SECONDARY
Time to Arrhythmia Termination for the Bipolar Group Only
14.33
SECONDARY
Total Duration of Bipolar Ablation
342.22; 317.33
SECONDARY
Number of of Participants With Mortality
9; 5

Summary

This non-randomized study will examine the safety and efficacy of irrigated bipolar radiofrequency (RF) ablation in the treatment of ventricular tachycardia (VT) in patients for whom standard VT unipolar RF ablation has been unsuccessful. VT is a serious abnormality of the heart's electrical system. Ablation is a procedure that cauterizes heart tissue using catheters (long tubes that can be moved within or along the outside of the heart). Cauterizing the heart tissue is accomplished by using heat to damage the abnormal heart tissue that is not working well so that it can stop affecting the rest of the heart. Usually, heat is delivered using a unipolar catheter, in which energy travels from the catheter tip to a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in which the energy travels between two catheter tips on either side of the heart muscle, can be used to eliminate the arrhythmia when the unipolar ablation is unsuccessful. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years of age.
  • The study will include all forms of scar VT--both ischemic (post-myocardial infarction) and non-ischemic (eg sarcoid, amyloid, dilated)--as determined by cardiac MRI and/or voltage mapping at the time of VT ablation.
  • Intramural VT not terminable with unipolar ablation once enrolled in the Bipolar study or previous failed unipolar ablation within 6 months prior to enrollment.
  • Ability to understand the requirements of the study and sign the informed consent form.
  • Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements
  • Projected lifespan greater than 1 year.

Exclusion Criteria

  • Tissue Thickness less than 5 mm as assessed by electroanatomic mapping, CT, or MRI.
  • MI or CABG within 6 weeks.
  • NYHA Class IV CHF.
  • Women known to be pregnant or to have positive beta-HCG.
  • Participation in another study that would interfere with this study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02374476). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search